Stem definition | Drug id | CAS RN |
---|---|---|
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics | 937 | 34368-04-2 |
Dose | Unit | Route |
---|---|---|
0.50 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.13 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
CL (Clearance) | 115 mL/min/kg | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 18, 1978 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Stress cardiomyopathy | 132.92 | 29.88 | 38 | 2726 | 7849 | 50594511 |
Cardiogenic shock | 85.06 | 29.88 | 32 | 2732 | 15567 | 50586793 |
Multiple organ dysfunction syndrome | 78.29 | 29.88 | 43 | 2721 | 50294 | 50552066 |
Local anaesthetic systemic toxicity | 58.66 | 29.88 | 12 | 2752 | 600 | 50601760 |
Drug ineffective | 58.07 | 29.88 | 133 | 2631 | 819200 | 49783160 |
Cardiac failure | 50.48 | 29.88 | 38 | 2726 | 76002 | 50526358 |
Status epilepticus | 37.24 | 29.88 | 17 | 2747 | 13389 | 50588971 |
Ureaplasma infection | 37.20 | 29.88 | 8 | 2756 | 510 | 50601850 |
Pulmonary hypertension | 34.67 | 29.88 | 22 | 2742 | 33395 | 50568965 |
Ventricular tachycardia | 34.56 | 29.88 | 17 | 2747 | 15804 | 50586556 |
Renal failure | 31.96 | 29.88 | 34 | 2730 | 106599 | 50495761 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Appendicolith | 329.22 | 28.68 | 80 | 4067 | 3400 | 29566980 |
Multiple organ dysfunction syndrome | 271.58 | 28.68 | 145 | 4002 | 62971 | 29507409 |
Appendicitis | 264.33 | 28.68 | 82 | 4065 | 8697 | 29561683 |
Stress | 236.87 | 28.68 | 95 | 4052 | 21395 | 29548985 |
Ascites | 168.00 | 28.68 | 88 | 4059 | 36531 | 29533849 |
Abdominal distension | 138.94 | 28.68 | 84 | 4063 | 45827 | 29524553 |
Ventricular fibrillation | 130.58 | 28.68 | 57 | 4090 | 15776 | 29554604 |
Sepsis | 110.79 | 28.68 | 117 | 4030 | 142565 | 29427815 |
General physical health deterioration | 103.13 | 28.68 | 97 | 4050 | 102760 | 29467620 |
Hyponatraemia | 102.84 | 28.68 | 81 | 4066 | 67552 | 29502828 |
Toxic epidermal necrolysis | 81.30 | 28.68 | 43 | 4104 | 18110 | 29552270 |
Constipation | 66.85 | 28.68 | 81 | 4066 | 114079 | 29456301 |
Off label use | 62.93 | 28.68 | 133 | 4014 | 300667 | 29269713 |
Cardiogenic shock | 62.81 | 28.68 | 37 | 4110 | 19153 | 29551227 |
Abdominal pain | 60.44 | 28.68 | 84 | 4063 | 135273 | 29435107 |
Drug ineffective | 51.43 | 28.68 | 138 | 4009 | 363032 | 29207348 |
Stress cardiomyopathy | 39.83 | 28.68 | 13 | 4134 | 1611 | 29568769 |
Vomiting | 36.48 | 28.68 | 87 | 4060 | 212173 | 29358207 |
Fear | 35.55 | 28.68 | 20 | 4127 | 9484 | 29560896 |
Anhedonia | 32.04 | 28.68 | 17 | 4130 | 7183 | 29563197 |
Injury | 31.42 | 28.68 | 24 | 4123 | 19022 | 29551358 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Appendicolith | 353.81 | 25.84 | 80 | 6557 | 3389 | 64488706 |
Multiple organ dysfunction syndrome | 308.35 | 25.84 | 167 | 6470 | 101246 | 64390849 |
Appendicitis | 253.87 | 25.84 | 82 | 6555 | 13487 | 64478608 |
Stress | 178.93 | 25.84 | 98 | 6539 | 60436 | 64431659 |
Ascites | 171.26 | 25.84 | 96 | 6541 | 61905 | 64430190 |
Ventricular fibrillation | 163.97 | 25.84 | 69 | 6568 | 23791 | 64468304 |
Stress cardiomyopathy | 149.17 | 25.84 | 50 | 6587 | 9207 | 64482888 |
Cardiogenic shock | 128.66 | 25.84 | 64 | 6573 | 32363 | 64459732 |
Abdominal distension | 123.69 | 25.84 | 92 | 6545 | 95902 | 64396193 |
Sepsis | 115.82 | 25.84 | 130 | 6507 | 230211 | 64261884 |
Drug ineffective | 108.34 | 25.84 | 254 | 6383 | 839993 | 63652102 |
General physical health deterioration | 78.98 | 25.84 | 101 | 6536 | 204324 | 64287771 |
Off label use | 76.53 | 25.84 | 187 | 6450 | 632619 | 63859476 |
Hyponatraemia | 73.16 | 25.84 | 83 | 6554 | 148256 | 64343839 |
Toxic epidermal necrolysis | 72.37 | 25.84 | 46 | 6591 | 37120 | 64454975 |
Ventricular tachycardia | 55.96 | 25.84 | 38 | 6599 | 34227 | 64457868 |
Fatigue | 51.29 | 25.84 | 8 | 6629 | 748722 | 63743373 |
Constipation | 50.41 | 25.84 | 87 | 6550 | 229250 | 64262845 |
Local anaesthetic systemic toxicity | 49.73 | 25.84 | 12 | 6625 | 673 | 64491422 |
Cardiac failure | 42.75 | 25.84 | 60 | 6577 | 132313 | 64359782 |
Right ventricular failure | 40.35 | 25.84 | 26 | 6611 | 21445 | 64470650 |
Abdominal pain | 37.16 | 25.84 | 92 | 6545 | 312283 | 64179812 |
Fear | 36.86 | 25.84 | 24 | 6613 | 20147 | 64471948 |
Hypernatraemia | 36.66 | 25.84 | 20 | 6617 | 12169 | 64479926 |
Renal impairment | 33.32 | 25.84 | 54 | 6583 | 134963 | 64357132 |
Status epilepticus | 32.94 | 25.84 | 23 | 6614 | 21640 | 64470455 |
Renal failure | 31.17 | 25.84 | 62 | 6575 | 181626 | 64310469 |
Electrocardiogram ST segment elevation | 30.76 | 25.84 | 15 | 6622 | 7244 | 64484851 |
Ventricular arrhythmia | 30.46 | 25.84 | 15 | 6622 | 7400 | 64484695 |
Torsade de pointes | 30.12 | 25.84 | 20 | 6617 | 17343 | 64474752 |
Renal injury | 29.77 | 25.84 | 19 | 6618 | 15410 | 64476685 |
Cardiomyopathy | 29.70 | 25.84 | 23 | 6614 | 25333 | 64466762 |
Ureaplasma infection | 29.34 | 25.84 | 8 | 6629 | 730 | 64491365 |
Anhedonia | 29.27 | 25.84 | 18 | 6619 | 13688 | 64478407 |
Eosinophilic myocarditis | 28.20 | 25.84 | 8 | 6629 | 844 | 64491251 |
Cardiac arrest | 28.15 | 25.84 | 54 | 6583 | 154010 | 64338085 |
Arthralgia | 27.47 | 25.84 | 6 | 6631 | 442254 | 64049841 |
None
Source | Code | Description |
---|---|---|
ATC | C01CA07 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
FDA MoA | N0000000245 | Adrenergic beta-Agonists |
FDA EPC | N0000175555 | beta-Adrenergic Agonist |
CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
CHEBI has role | CHEBI:35524 | sympathomimetic |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D000322 | Adrenergic Agonists |
MeSH PA | D058665 | Adrenergic beta-1 Receptor Agonists |
MeSH PA | D000318 | Adrenergic beta-Agonists |
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D013566 | Sympathomimetics |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Cardiogenic shock | indication | 89138009 | |
Decompensated cardiac failure | indication | 195111005 | |
Stress echocardiography using dobutamine | indication | 703338002 | |
Cardiac Decompensation | indication | ||
Cardiac Decompensation Post Cardiac Surgery | indication | ||
Organic Cardiac Disease | indication | ||
Ventricular premature beats | contraindication | 17338001 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypovolemia | contraindication | 28560003 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hypokalemia | contraindication | 43339004 | |
Atrial fibrillation | contraindication | 49436004 | DOID:0060224 |
Aortic valve stenosis | contraindication | 60573004 | DOID:1712 |
Idiopathic hypertrophic subaortic stenosis | contraindication | 360465008 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.98 | acidic |
pKa2 | 10.59 | acidic |
pKa3 | 13.49 | acidic |
pKa4 | 9.03 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-2 adrenergic receptor | GPCR | AGONIST | EC50 | 6.20 | WOMBAT-PK | CHEMBL | |||
Beta-1 adrenergic receptor | GPCR | AGONIST | EC50 | 5.50 | WOMBAT-PK | CHEMBL | |||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.40 | DRUG MATRIX | |||||
Catechol O-methyltransferase | Enzyme | Km | 4.30 | WOMBAT-PK | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 5.98 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.00 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.42 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.87 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.77 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 6.91 | DRUG MATRIX | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 6.32 | CHEMBL | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 7.35 | DRUG MATRIX | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 5.72 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 5.05 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 5.01 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 5.36 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | IC50 | 5.26 | DRUG MATRIX | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 6.14 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 6.05 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 5.13 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 5.02 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 4.92 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 5.38 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 5.02 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 5.37 | CHEMBL | |||||
Tyrosine-protein kinase Lck | Kinase | IC50 | 5.26 | DRUG MATRIX | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 6.73 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.80 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 6.96 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 6.41 | CHEMBL |
ID | Source |
---|---|
4019730 | VUID |
N0000147822 | NUI |
D00632 | KEGG_DRUG |
49745-95-1 | SECONDARY_CAS_RN |
203121 | RXNORM |
4017541 | VANDF |
4019730 | VANDF |
C0012963 | UMLSCUI |
CHEBI:4670 | CHEBI |
Y00 | PDB_CHEM_ID |
CHEMBL926 | ChEMBL_ID |
DB00841 | DRUGBANK_ID |
CHEMBL1200418 | ChEMBL_ID |
D004280 | MESH_DESCRIPTOR_UI |
36811 | PUBCHEM_CID |
535 | IUPHAR_LIGAND_ID |
3340 | INN_ID |
3S12J47372 | UNII |
2871 | MMSL |
4625 | MMSL |
d00215 | MMSL |
000614 | NDDF |
000615 | NDDF |
26523005 | SNOMEDCT_US |
387145002 | SNOMEDCT_US |
90118002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dobutamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1073 | INJECTION | 100 mg | INTRAVENOUS | NDA | 18 sections |
Dobutamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1075 | INJECTION | 200 mg | INTRAVENOUS | NDA | 18 sections |
Dobutamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1077 | INJECTION | 400 mg | INTRAVENOUS | NDA | 18 sections |
DOBUTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2344 | INJECTION, SOLUTION, CONCENTRATE | 12.50 mg | INTRAVENOUS | ANDA | 21 sections |
DOBUTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2344 | INJECTION, SOLUTION, CONCENTRATE | 12.50 mg | INTRAVENOUS | ANDA | 21 sections |
Dobutamine in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2346 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 12 sections |
Dobutamine in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2347 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | NDA | 12 sections |
Dobutamine in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3724 | INJECTION, SOLUTION | 400 mg | INTRAVENOUS | NDA | 12 sections |
Dobutamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4562 | INJECTION | 400 mg | INTRAVENOUS | NDA | 18 sections |
DOBUTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1330 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | NDA | 12 sections |
DOBUTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1337 | INJECTION, SOLUTION, CONCENTRATE | 12.50 mg | INTRAVENOUS | ANDA | 12 sections |
DOBUTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1337 | INJECTION, SOLUTION, CONCENTRATE | 12.50 mg | INTRAVENOUS | ANDA | 12 sections |
DOBUTAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1566 | INJECTION | 100 mg | INTRAVENOUS | NDA | 11 sections |
Dobutamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5717 | INJECTION, SOLUTION | 12.50 mg | INTRAVENOUS | ANDA | 11 sections |
Dobutamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5777 | INJECTION, SOLUTION | 400 mg | INTRAVENOUS | NDA | 12 sections |